The clinical use of long-term growth hormone treatment is increasing and such treatment leads to raised IGF-1 levels. Increased insulin levels are also more common as the prevalence of insulin resistance, which frequently presages obesity and/or type 2 diabetes, increases in the population. Therefore, a careful discussion of the role of IGF-1 and insulin in various cancers is urgently needed. This book examines these issues in detail. It features contributions from the leading scientists and clinicians in the field and should prove essential reading for anyone with a clinical interest in insulin and the IGFs.